Comparison of Efficacy and Safety of 5-Day and 10-Day Schedules of Sgi-110, a Novel Subcutaneous (Sc) Hypomethylating Agent (Hma), in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (R/R Aml)

Efficacy and Safety of Azacytidine in combination with fludarabine and high-dose cytarabine with G-CSF (FLAG) in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/j.clml.2021.07.019 ◽

2021 ◽

Author(s):

Ibraheem H. Motabi ◽

Shaima M. Al Aoun ◽

Maged Al-Ammari ◽

Belal M. Albtoosh ◽

Shahid Iqbal ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Myeloid Leukemia ◽

Phase Ii Study ◽

High Dose ◽

Efficacy And Safety ◽

Open Label ◽

High Dose Cytarabine ◽

Open Label Phase ◽

Efficacy and Safety of Unmanipulated Haploidentical Related Donor Allogeneic Peripheral Blood Stem Cell Transplantation in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Chinese Medical Journal ◽

10.4103/0366-6999.228243 ◽

2018 ◽

Vol 131 (7) ◽

pp. 790-798 ◽

Cited By ~ 4

Author(s):

Li-Ping Dou ◽

Hong-Hua Li ◽

Lu Wang ◽

Fei Li ◽

Wen-Rong Huang ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Stem Cell ◽

Stem Cell Transplantation ◽

Myeloid Leukemia ◽

Peripheral Blood Stem Cell ◽

Efficacy And Safety ◽

Related Donor ◽

Blood Stem Cell Transplantation ◽

Efficacy and Safety of CPX-351 Versus 7+3 in a Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia (sAML) with Prior Hypomethylating Agent (HMA) Exposure Who Achieved Remission

Biology of Blood and Marrow Transplantation ◽

10.1016/j.bbmt.2019.12.605 ◽

2020 ◽

Vol 26 (3) ◽

pp. S102

Author(s):

Tara Lin ◽

Daniel H. Ryan ◽

Ellen K. Ritchie ◽

Stephen A. Strickland ◽

Donna E. Hogge ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

High Risk ◽

Myeloid Leukemia ◽

Exploratory Analysis ◽

Efficacy And Safety ◽

Phase 3 ◽

Secondary Acute Myeloid Leukemia ◽

Hypomethylating Agent ◽

Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia

Leukemia & Lymphoma ◽

10.1080/10428194.2018.1468893 ◽

2018 ◽

Vol 60 (1) ◽

pp. 246-249

Author(s):

Maximilian Stahl ◽

Michelle DeVeaux ◽

Pau Montesinos ◽

Raphaël Itzykson ◽

Ellen K. Ritchie ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Medical Research ◽

Survival Benefit ◽

Myeloid Leukemia ◽

Research Council ◽

Medical Research Council ◽

Hypomethylating Agent ◽

Hypomethylating agent (HMA) treatment as a bridge to allogeneic hematopoietic cell transplantation (HCT) for relapsed/refractory acute myeloid leukemia (RR-AML).

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.7033 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 7033-7033 ◽

Cited By ~ 1

Author(s):

Michael Richard Grunwald ◽

Danielle Boselli ◽

Lauren M. Bohannon ◽

Michael Keith Alister Zimmerman ◽

Jing Ai ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Cell Transplantation ◽

Myeloid Leukemia ◽

Hematopoietic Cell Transplantation ◽

Hematopoietic Cell ◽

Allogeneic Hematopoietic Cell Transplantation ◽

Hypomethylating Agent ◽

Efficacy and safety of quizartinib in Japanese patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia in an open-label, phase 2 study

International Journal of Hematology ◽

10.1007/s12185-019-02727-6 ◽

2019 ◽

Vol 110 (6) ◽

pp. 665-674 ◽

Cited By ~ 3

Author(s):

Takeshi Takahashi ◽

Kensuke Usuki ◽

Kosei Matsue ◽

Hitoshi Ohno ◽

Toru Sakura ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Myeloid Leukemia ◽

Japanese Patients ◽

Phase 2 ◽

Efficacy And Safety ◽

Open Label ◽

Phase 2 Study ◽

Open Label Phase ◽

Low-dose melphalan in elderly patients with relapsed or refractory acute myeloid leukemia: A well-tolerated and effective treatment after hypomethylating-agent failure

Leukemia Research ◽

10.1016/j.leukres.2019.106192 ◽

2019 ◽

Vol 85 ◽

pp. 106192 ◽

Cited By ~ 2

Author(s):

Jan Stratmann ◽

Elisabeth van Kann ◽

Christoph Rummelt ◽

Sebastian Koschade ◽

Christoph Röllig ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Elderly Patients ◽

Effective Treatment ◽

Myeloid Leukemia ◽

Low Dose ◽

Hypomethylating Agent ◽

AML-149: Efficacy and Safety of Azacytidine in Combination with Fludarabine and High-Dose Cytarabine with G-CSF (FLAG) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Open-Label, Phase II Study

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/s2152-2650(21)01682-7 ◽

2021 ◽

Vol 21 ◽

pp. S284

Author(s):

Shaima Al Aoun ◽

Ibraheem Motabi ◽

Maged Al Ammari ◽

Nawal Al lshehry ◽

Mohammed Marei ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Myeloid Leukemia ◽

Phase Ii Study ◽

High Dose ◽

Efficacy And Safety ◽

Open Label ◽

High Dose Cytarabine ◽

Open Label Phase ◽

First results of a phase 2 study using a 10-day subcutaneous (SC) regimen of the novel hypomethylating agent (HMA) SGI-110 for the treatment of relapsed/refractory acute myeloid leukemia (r/r AML).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.7030 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 7030-7030 ◽

Cited By ~ 4

Author(s):

Elizabeth A. Griffiths ◽

Hagop M. Kantarjian ◽

Gail J. Roboz ◽

Patricia Lamont Kropf ◽

Casey Lee O'Connell ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Myeloid Leukemia ◽

The Novel ◽

Phase 2 ◽

Hypomethylating Agent ◽

Phase 2 Study ◽

First Results ◽

Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens

Haematologica ◽

10.3324/haematol.2020.252569 ◽

2020 ◽

pp. haematol.2020.252569 ◽

Cited By ~ 3

Author(s):

Abhishek Maiti ◽

Caitlin R. Rausch ◽

Jorge E. Cortes ◽

Naveen Pemmaraju ◽

Naval G. Daver ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Myeloid Leukemia ◽

Hypomethylating Agent ◽